GlassScriptPhysician profile
Ricardo Roman
NPI 1144327032
$35,197.30
in general payments reported to CMS, 2019-2025
66 companies · $4,764 in 2025
The $4,764 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,718 · 2020: $1,976 · 2021: $3,215 · 2022: $4,156 · 2023: $6,904 · 2024: $7,465 · 2025: $4,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Travel and Lodging: $13.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,119.48 |
| Travel and Lodging | $13.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,757.68 | 2019-2025 | Skyrizi, Rinvoq, Qulipta |
| Astrazeneca Pharmaceuticals LP | $4,432.81 | 2019-2025 | Airsupra, Fasenra, Farxiga |
| Amgen INC. | $2,193.18 | 2019-2024 | Evenity, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,620.62 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $1,559.62 | 2021-2025 | Arexvy, Nucala, Ojjaara |
| Novo Nordisk INC | $1,519.75 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Gilead Sciences, INC. | $1,376.80 | 2019-2025 | Veklury, Trodelvy, Vemlidy |
| Teva Pharmaceuticals USA, INC. | $1,355.49 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lilly USA, LLC | $1,310.75 | 2019-2025 | Taltz, Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $1,156.65 | 2021-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $1,088.36 | 2021-2023 | Imbruvica |
| Boehringer Ingelheim Pharmaceuticals, INC. | $866.37 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $803.78 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $614.13 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Biotech, INC. | $520.54 | 2023-2025 | Rybrevant, Carvykti, Imbruvica |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.